Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Badr, Gamal ^a,b,c   Mohany, Mohamed ^a   Abu Tarboush, Faisal ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Assiut University   (Egypt)

Author keywords

Cytoskeleton; multiple myeloma; proliferation; signaling; thymoquinone

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; F ACTIN; INTERLEUKIN 6; PROTEIN BCL 2; PROTEIN BCL XL; STAT3 PROTEIN; STAT5 PROTEIN; THYMOQUINONE;

ACTIN POLYMERIZATION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; HUMAN; HUMAN CELL; IC 50; MULTIPLE MYELOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ACTINS; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOKINE CXCL12; GENE EXPRESSION; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-BCL-2; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

NIGELLA SATIVA;

EID: 83455203366     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-236     Document Type: Article

References (31)

1. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Hideshima T, Bradner J, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC, Proc Natl Acad Sci USA 2005 102 8567 8572 10.1073/pnas.0503221102 15937109 (Pubitemid 40862776)
2. Single versus double autologous stem-cell transplantation for multiple myeloma. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R, N Engl J Med 2003 349 2495 2502 10.1056/NEJMoa032290 14695409 (Pubitemid 38010075)
3. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Yasui H, Hideshima T, Richardson PG, Anderson KC, Br J Haematol 2006 132 385 397 16412014 (Pubitemid 43381614)
4. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. Xu JL, Lai R, Kinoshita T, Nakashima N, Nagasaka T, J Clin Pathol 2002 55 530 534 10.1136/jcp.55.7.530 12101201 (Pubitemid 34779306)
5. Cellular motility driven by assembly and disassembly of actin filaments. Pollard TD, Borisy GG, Cell 2003 112 453 65 10.1016/S0092-8674(03)00120-X 12600310 (Pubitemid 36263079)
6. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha U, Blood 2007 109 2714 2715
7. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H, Ann N Y Acad Sci 2006 1091 151 169 10.1196/annals.1378.063 17341611 (Pubitemid 47092233)
8. STATs in oncogenesis. Bowman T, Garcia R, Turkson J, Jove R, Oncogene 2000 19 2474 2488 10.1038/sj.onc.1203527 10851046 (Pubitemid 30339203)
9. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H, Oncogene 2002 21 7001 7010 10.1038/sj.onc.1205859 12370822 (Pubitemid 35252974)
10. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ, Oncogene 2002 21 8404 8413 10.1038/sj.onc.1206047 12466961 (Pubitemid 36054883)
11. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL, Oncogene 2002 21 7611 7618 10.1038/sj.onc.1206004 12400004 (Pubitemid 35398808)
12. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H, Wetzler M, Blood 2002 99 252 257 10.1182/blood.V99.1.252 11756179 (Pubitemid 34532991)
13. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, Weinstein IB, Cancer Res 2002 62 3351 3355 12067972 (Pubitemid 34651376)
14. Thymoquinone a promising anti-cancer drug from natural sources. Gali-Muhtasib H, Roessner A, Schneider-Stock R, Int J Biochem Cell Biol 2006 38 1249 1253 10.1016/j.biocel.2005.10.009 16314136
15. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK, Int J Oncol 2003 22 107 113 12469192
16. Modes of action of alpha-hederin and thymoquinone, active constituents of Nigella sativa, against HEp-2 cancer cells. Rooney S, Ryan MF, Anticancer Res 2005 25 4255 9 16309225 (Pubitemid 41665213)
17. Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Ravindran J, Nair HB, Sung B, Prasad S, Tekmal RR, Aggarwal BB, Biochem Pharmacol 2010 79 1640 7 10.1016/j.bcp.2010.01.023 20105430
18. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Li F, Rajendran P, Sethi G, Br J Pharmacol 2010 161 541 554 10.1111/j.1476-5381.2010.00874.x 20880395
19. Reproducible obtaining of human myeloma cell lines as a model for tumor stemcell study in human multiple myeloma. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B, Blood 1994 83 3654 3663 8204890 (Pubitemid 24175556)
20. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Puthier D, Bataille R, Amiot M, Eur J Immunol 1999 29 3945 3950 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0. CO;2-O 10602002
21. HIV type 1 glycoprotein 120 inhibits human B cell chemotaxis to CXC chemokine ligand (CXCL) 12, CC chemokine ligand (CCL) 20, and CCL21. Badr G, Borhis G, Treton D, Moog C, Garraud O, Richard Y, J Immunol 2005 175 1 302 10 15972662 (Pubitemid 40884332)
22. In Vitro Challenge using Thymoquinone on Hepatocellular Carcinoma (HepG2) Cell Line. Hassana SA, Ahmedb WA, Galebc MF, El-Taweeld MA, Abu-Beda FA, Iranian Journal of Pharmaceutical Research 2008 7 283 290
23. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, Sethi G, Aggarwal BB, Liu M, Mol Cancer Ther 2008 7 1789 1796 10.1158/1535-7163.MCT-08-0124 18644991
24. Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Koka PS, Mondal D, Schultz M, Abdel-Mageed AB, Agrawal KC, Exp Biol Med (Maywood) 2010 235 751 760 10.1258/ebm.2010.009369
25. Regulation of cancer cell motility through actin reorganization. Yamazaki D, Kurisu S, Takenawa T, Cancer Sci 2005 96 379 386 10.1111/j.1349-7006.2005. 00062.x 16053508 (Pubitemid 41179738)
26. Elevated serum levels of stromal derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S, Cancer Res 2005 65 1700 1709 10.1158/0008-5472.CAN-04-1687 15753365 (Pubitemid 40478595)
27. Interleukin-6 in human multiple myeloma. Klein B, Zhang XG, Lu ZY, Bataille R, Blood 1995 85 863 872 7849308
28. Vascular endo- thelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J, Blood 2000 95 2630 2636 10753844 (Pubitemid 30210543)
29. Role of Interleukin-6 in the pathogenesis of multiple myeloma. Gado K, Domjan G, Hegyesi H, Falus A, Cell Biol Int 2000 24 195 209 10.1006/cbir.2000. 0497 10816321
30. Stat3 as an oncogene. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE, Cell 1999 98 295 303 10.1016/S0092-8674(00) 81959-5 10458605 (Pubitemid 29380565)
31. Interferon alpha extends the survival of human myelom cells through an upregulation of the Mcl-1 antiapoptotic molecule. Puthier D, Thabard W, Rapp M, Etrillard M, Harousseau J, Bataille R, Amiot M, Br J Haematol 2001 112 358 363 10.1046/j.1365-2141.2001.02575.x 11167829 (Pubitemid 32183477)